Improved outcomes with modern lung-sparing trimodality therapy in patients with malignant pleural mesothelioma Journal Article
| Authors: | Shaikh, F.; Zauderer, M. G.; von Reibnitz, D.; Wu, A. J.; Yorke, E. D.; Foster, A.; Shi, W.; Zhang, Z.; Adusumilli, P. S.; Rosenzweig, K. E.; Krug, L. M.; Rusch, V. W.; Rimner, A. |
| Article Title: | Improved outcomes with modern lung-sparing trimodality therapy in patients with malignant pleural mesothelioma |
| Abstract: | Introduction Higher target conformity and better sparing of organs at risk with modern radiotherapy (RT) may result in higher tumor control and less toxicity. In this study, we compare our institutional multimodality therapy experience of adjuvant chemotherapy and hemithoracic intensity-modulated pleural RT (IMPRINT) with previously used adjuvant conventional RT (CONV) in patients with malignant pleural mesothelioma (MPM) treated with lung-sparing pleurectomy/decortication (P/D). Methods We analyzed 209 patients who underwent P/D and adjuvant RT (131 who received CONV and 78 who received IMPRINT) for MPM between 1974 and 2015. The primary end point was overall survival (OS). The Kaplan-Meier method and Cox proportional hazards model were used to calculate OS; competing risks analysis was performed for local failure-free survival and progression-free survival. Univariate analysis and multivariate analysis were performed with relevant clinical and treatment factors. Results The median age was 64 years, and 80% of the patients were male. Patients receiving IMPRINT had significantly higher rates of the epithelial histological type, advanced pathological stage, and chemotherapy treatment. OS was significantly higher after IMPRINT (median 20.2 versus 12.3 months, p = 0.001). Higher Karnofsky performance score, epithelioid histological type, macroscopically complete resection, and use of chemotherapy/IMPRINT were found to be significant factors for longer OS in multivariate analysis. No significant predictive factors were identified for local failure or progression. Grade 2 or higher esophagitis developed in fewer patients after IMPRINT than after CONV (23% versus 47%). Conclusions Trimodality therapy including adjuvant hemithoracic IMPRINT, chemotherapy, and P/D is associated with promising OS rates and decreased toxicity in patients with MPM. Dose constraints should be applied vigilantly to minimize serious adverse events. © 2017 International Association for the Study of Lung Cancer |
| Keywords: | pleurectomy/decortication; malignant pleural mesothelioma; conventional rt; imprint; intensity-modulated pleural radiation therapy |
| Journal Title: | Journal of Thoracic Oncology |
| Volume: | 12 |
| Issue: | 6 |
| ISSN: | 1556-0864 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2017-06-01 |
| Start Page: | 993 |
| End Page: | 1000 |
| Language: | English |
| DOI: | 10.1016/j.jtho.2017.02.026 |
| PROVIDER: | scopus |
| PUBMED: | 28341225 |
| PMCID: | PMC5499250 |
| DOI/URL: | |
| Notes: | Conference Paper -- Export Date: 1 June 2017 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work